Automated visual inspection systems generate vast amounts of data, but most pharmaceutical manufacturers struggle to turn that data into actionable quality intelligence. Here’s what’s holding the industry back and how to move forward.
Automated visual inspection (AVI) is a key stage of pharmaceutical quality control process. Camera-based systems inspect filled containers at high speed, flagging particles, cracks, and cosmetic defects with consistency that manual inspection cannot match. The technology works, but there is more on the table.
At the recent PDA Visual Inspection Forum in Dublin, the discussions made it clear that the difficulties manufacturers face with inspection data are not isolated issues, but industry-wide patterns that nearly everyone is grappling with.
Every inspection generates data: images, defect classifications, reject decisions, process parameters. Yet in most facilities, this data remains underutilized. Pass/fail decisions are made, rejected units are discarded or reviewed, and the underlying patterns that could drive continuous improvement remain invisible. The gap between data generated and actually putting it to use is where both the real opportunity and the real challenge lie.
The False Reject Problem: A Symptom of Deeper Issues
One of the most visible pain points in AVI is the false reject rate. At the PDA Visual Inspection Forum, attendees were asked to rank the top reasons for efficiency losses in visual inspection. The results were unambiguous: scrap and yield loss due to false rejects ranked first, ahead of line stops, investigations, re-inspections, and equipment downtime.
Systems tuned for high sensitivity catch more defects but also flag clean units as rejects. The result is wasted product, increased manual review workload, and operator frustration. When false reject rates spike, the typical response is reactive: pull samples, review images manually, and try to identify what shifted. In fact, when asked what their first move would be if the false reject rate doubled, half of forum attendees said they would pull samples to review what changed. This approach treats the symptom, not the cause.
The underlying issue is that rule-based systems can only detect what they have been explicitly programmed to recognize. When process conditions shift (e.g. new packaging materials, formulation changes, lighting variations) the system does not generalize to acceptable variation. It continues applying the same rigid thresholds, which cannot distinguish product variation from genuine defects, which results in false rejects at rates that scale with process variability.
That is why the false reject problem is, at its core, a data problem: understanding what shifted, and retuning the system accordingly, requires structured inspection data collected over time. Without it, quality teams cannot distinguish systematic issues from random variation, and root cause analysis becomes guesswork.
What the Industry Is Facing: Common Challenges Across Pharma Manufacturing
Across pharmaceutical manufacturing, the same patterns emerge. Companies invest in AVI systems, achieve initial improvements in throughput and consistency, and then hit a ceiling. The technology is in place, but without systematic data harmonization, the vast amount of information generated remains siloed, and processes cannot be improved.
When forum attendees were asked where their organizations are experiencing the most pain today, the responses were spread across the entire workflow: particle investigations (28%), AVI validation and regulatory alignment (23%), complex data presentations and deviation investigations (23%), and high false reject rates (15%). Inspector variability accounts for the remaining 11%. No single fix addresses a spread like that, but the common thread is how inspection data is captured and connected.
Challenge 1: Inspection data remains disconnected from quality intelligence
AVI systems produce pass/fail signals, but that data rarely integrates with broader quality management systems. When systems flag units for review, operators make decisions, yet the outcomes like confirmed defects, false alarms, and borderline cases are not systematically captured or analyzed. Defect trends are not correlated with upstream process parameters. The same ambiguous defect types appear repeatedly, and the system does not connect the dots.
Challenge 2: Regulatory frameworks are evolving faster than internal capabilities
The draft EU GMP Annex 22 signals a shift toward more structured use of AI and data-driven quality systems. Regulatory expectations are rising, but many organizations lack the data infrastructure to meet them. Compliance becomes a barrier rather than a driver of improvement.
Challenge 3: AI implementation without data maturity fails
There is growing interest in AI-powered inspection, but deploying AI models on top of fragmented, inconsistent data does not work. Machine learning requires harmonized, clean, and historically consistent datasets. Without that foundation of data harmonization, AI projects stall in proof-of-concept phases and never reach production.
The Path Forward: From Data Generation to Data Harmonization
The solution to the AVI bottleneck is not simply capturing more images or purchasing faster machines. It is building the data infrastructure required to turn disparate inspection outputs into a unified stream of quality intelligence. The industry consensus on this long-term direction is remarkably unified. When attendees at the PDA forum were asked to name the single most important capability needed by 2030, the dominant response in the word cloud was unmistakable: harmonization.
In our experience, true harmonization is the essential bridge between raw data collection and scalable AI capability. It means moving away from isolated, machine-specific databases toward an integrated quality ecosystem where data, human expertise, and automation work in sync. To begin this transition, we advise focusing on four critical dimensions:
- Standardize data schemas across systems: Every inspection decision, including the images, metadata, and final classifications, must be captured in a unified format. This is the only way to make historical data queryable and ready for future model training.
- Align human decision-making with automation: Harmonization means connecting human review outcomes directly back to the AVI algorithms. When an operator reviews an ambiguous unit and overrides a false reject, that feedback must be structured so that the machine learning models can learn from it over time.
- Connect upstream and downstream quality signals: Visual inspection should not operate in a vacuum. By harmonizing visual defect patterns with upstream process variables (such as raw material lots, fill-line pressures, or formulation conditions), the AVI system is transformed from a passive gatekeeper into a proactive process diagnostic tool.
- Build the validation pedigree required for AI: Regulatory guidelines like draft Annex 22 expect documented, representative, and traceable datasets. Harmonized data architectures provide the clean, validated data lineage that makes machine learning models audit-ready and deployable under GxP rules.
What This Means for Quality Leaders
Pharmaceutical quality management is shifting from reactive verification to proactive process intelligence. Visual inspection is part of that shift, but only if the data it generates is put to work.
The companies that will lead in this space are not necessarily the ones with the most advanced cameras or the fastest lines. They are the ones that treat inspection data as a strategic asset, build the infrastructure to manage it, and use it to drive continuous improvement.
The technology is ready. The question is whether quality systems are ready to evolve with it.
***
StatSoft has delivered advanced analytics solutions for highly regulated manufacturing environments for over 30 years. Our solutions integrate AI-powered visual inspection, process analytics, and quality intelligence into unified platforms designed specifically for pharmaceutical production.
